All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019.
RMD Open
; 7(3)2021 11.
Article
in English
| MEDLINE | ID: covidwho-1504941
ABSTRACT
OBJECTIVES:
To compare current all-cause mortality rates in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) versus general population.METHODS:
In this population-based, retrospective cohort study, anonymised data on 11 186 586 citizens, including all patients with RA (42 735, 79% female), AS (9707, 43% female), PsA (13 779, 55% female), SLE (10 440, 89% female) and SSc (2277, 88% female), (median age of 64/47/54/53/59 years at study entry, respectively), under prescribed treatment between 2015 and 2019, were extracted from the electronic database covering nearly 99% of the Greek population.RESULTS:
After 15 (patientsgeneral population) matching for gender/age, we found that survival was worse in SSc, followed by SLE and inflammatory arthritis. Compared with the general population HRs for death increased from the first 3 years to 5 years of observation possibly due to increases in disease duration RA (from 0.63 to 1.13 (95% CI 1.05 to 1.22), AS (from 0.62 to 1.01, (95% CI 0.76 to 1.33)), PsA (from 0.68 to 1.06, (95% CI 0.88 to 1.28)), SLE (from 1.52 to 1.98, (95% CI 1.67 to 2.33)) and SSc (from 2.27 to 4.24, (95% CI 3.19 to 5.63)). In both SLE and SSc mortality was increased in men than women and in patients younger than 50 years.CONCLUSIONS:
Survival rates over 5 years in inflammatory arthritis under treatment are currently becoming comparable (AS/PsA) or slightly higher (RA) than those of the general population. However, all-cause mortality is almost twofold and fourfold higher in SLE and SSc, respectively, being even higher for male and younger patients.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Arthritis, Psoriatic
/
Rheumatic Diseases
/
Lupus Erythematosus, Systemic
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Rmdopen-2021-001694
Similar
MEDLINE
...
LILACS
LIS